Compare CPIX & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPIX | FGEN |
|---|---|---|
| Founded | 1999 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.5M | 35.6M |
| IPO Year | 2009 | 2014 |
| Metric | CPIX | FGEN |
|---|---|---|
| Price | $5.09 | $9.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $146.50 |
| AVG Volume (30 Days) | ★ 274.9K | 41.1K |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 53.38 |
| Revenue | ★ $41,278,349.00 | $8,298,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.17 |
| Revenue Growth | ★ 12.21 | N/A |
| 52 Week Low | $1.85 | $4.85 |
| 52 Week High | $7.25 | $21.94 |
| Indicator | CPIX | FGEN |
|---|---|---|
| Relative Strength Index (RSI) | 81.76 | 56.61 |
| Support Level | $3.76 | $8.50 |
| Resistance Level | $4.11 | $9.32 |
| Average True Range (ATR) | 0.45 | 0.49 |
| MACD | 0.07 | 0.11 |
| Stochastic Oscillator | 85.14 | 94.67 |
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.